Ardelyx ARDX R&D credit carryforward
R&D credit carryforward at other companies
Other financials
Where this comes from
Reported directly by Ardelyx in its filing.
Tagged under the XBRL concept us-gaap:DeferredTaxAssetsTaxCreditCarryforwardsResearch.
The official record: Ardelyx’s 10-K, filed February 19, 2026, on SEC EDGAR. View the filing →
Ask your AI about Ardelyx's r&d credit carryforward.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Ardelyx's r&d credit carryforward?
- Ardelyx (ARDX) reported r&d credit carryforward of $17.11M in Q4 2025.
- How has Ardelyx's r&d credit carryforward changed year-over-year?
- Ardelyx's r&d credit carryforward increased by 10.2% year-over-year, from $15.53M to $17.11M.
- What is the long-term trend for Ardelyx's r&d credit carryforward?
- Over 5 years (2020 to 2025), Ardelyx's r&d credit carryforward has grown at a 7.8% compound annual growth rate (CAGR), from $11.78M to $17.11M.
- What does r&d credit carryforward mean?
- The value of accumulated research and development tax credits that the company can apply to reduce future tax liabilities. These carryforwards are significant assets for biotechnology firms that often incur losses during the development phase. They represent potential future cash flow savings once the company achieves sustained profitability.